Reviva Pharmaceuticals has obtained $4.8 million in financing to keep developing its treatments for pulmonary arterial hypertension (PAH) and other diseases.
Articles by Patrícia Silva, PhD
The Pulmonary Hypertension Association has accredited three more regional clinics that have demonstrated an ability to deliver high-quality care to…
Two pulmonary arterial hypertension experts will speak to investment professionals at a gathering in New York this week that Arena…
Patient enrollment is complete in a Phase 2 clinical trial of ubenimex as an add-on to standard therapy for pulmonary arterial hypertension…
Third Pole has won a Johnson & Johnson Innovation award for a lighter device that provides an unlimited supply of nitric…
The new pulmonary endarterectomy (PEA) surgery simulator — a 3D device developed by the National Research Council of Canada with support from …
Germany’s enmodes won recognition at the recent 2017 Design of Medical Devices Conference in Minneapolis for its RAS-Q technology to help people with…
Movie-goers will be seeing pulmonary hypertension public service announcements at selected theaters in California, Nevada and Washington, beginning today, which…
SteadyMed announced it has received a U.S. patent for its PatchPump infusion system for injectable drugs, including Trevyent, the company’s lead…
The Pulmonary Hypertension Association of Canada will be trying to persuade medical professionals to pay more attention to pulmonary…
Dr. C. Gregory Elliott has won the 2017 American Thoracic Society Public Advisory Roundtable William J. Martin, II Distinguished Achievement Award.
The patch that delivers SteadyMed’s pulmonary arterial hypertension (PAH) treatment Trevyent (treprostinil) to patients is effective, safe and tolerable, according to a…